OMERS ADMINISTRATION Corp Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

OMERS ADMINISTRATION Corp boosted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,166 shares of the medical research company's stock after acquiring an additional 2,705 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Amgen were worth $6,299,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Beck Mack & Oliver LLC raised its position in shares of Amgen by 0.7% during the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock worth $1,205,000 after acquiring an additional 34 shares in the last quarter. Blossom Wealth Management increased its holdings in shares of Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock valued at $284,000 after purchasing an additional 37 shares during the period. Zullo Investment Group Inc. increased its holdings in shares of Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after purchasing an additional 37 shares during the period. Trillium Asset Management LLC boosted its stake in shares of Amgen by 4.2% in the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock valued at $237,000 after buying an additional 37 shares in the last quarter. Finally, Evermay Wealth Management LLC boosted its stake in shares of Amgen by 1.5% in the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock valued at $691,000 after buying an additional 38 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMGN. UBS Group reiterated a "neutral" rating and set a $315.00 target price (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Piper Sandler decreased their target price on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday. Mizuho increased their target price on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald assumed coverage on Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average target price of $310.18.

Insider Buying and Selling

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. The trade was a 40.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.76% of the stock is owned by insiders.

Amgen Stock Up 0.3%

NASDAQ:AMGN traded up $0.72 on Friday, hitting $272.41. The stock had a trading volume of 2,588,369 shares, compared to its average volume of 2,789,152. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market cap of $146.48 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm's fifty day simple moving average is $291.00 and its two-hundred day simple moving average is $288.28.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the firm earned $3.96 EPS. The company's revenue was up 9.4% compared to the same quarter last year. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.49%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.